Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Three dates available!
Thursday, June 27, 2019, 12:00 PM - 1:00 PM CT - Register to attend June 27
Thursday, July 11, 2019, 11:00 AM - 12:00 PM CT - Register to attend July 11
Wednesday, July 24, 2019, 1:00 PM - 2:00 PM CT - Register to attend July 24
Improving practice and knowledge around the field of anticoagulation reversal is vital to appropriate care of patients. Pharmacists are in a critical role to help other health care professionals analyze and evaluate the appropriateness or necessity of bleeding reversal. This activity will include an overview of the types of major bleeding and available reversal agents along with treatment options. Discussion of procurement and availability will also be included.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
Katelyn W. Sylvester, PharmD, CACP, BCPS
Pharmacy Manager – Anticoagulation Services
Department of Pharmacy
Brigham and Women’s Hospital
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-19-195-L01-P has been assigned to this live knowledge-based activity (initial release date 6-27-2019). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation no later than July 26, 2019 to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation. Faculty conflict
of interest will be announced prior to the start of the activity.
Please note: The opinions expressed in this activity should not be construed as those of the CE provider or Portola Pharmaceuticals, Inc. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This activity is provided by ProCE, Inc. and is supported by an educational grant from Portola Pharmaceuticals, Inc.
Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.